View : 219 Download: 0
Clinical safety and effectiveness of the Genoss drug-eluting stent in real-world clinical practice
- Title
- Clinical safety and effectiveness of the Genoss drug-eluting stent in real-world clinical practice
- Authors
- Youn Y.J.; Lee J.-W.; Ahn S.G.; Lee S.-H.; Yoon J.; Park J.H.; Yoo S.-Y.; Kang W.C.; Lee N.H.; Kwon K.H.; Doh J.H.; Lim S.-W.; Jang Y.S.; Jeon D.W.; Heo J.H.; Choi W.G.; Cho S.; Lee B.-K.; Jeong H.; Hong B.-K.; Choi H.-H.
- Ewha Authors
- 권기환
- SCOPUS Author ID
- 권기환
- Issue Date
- 2023
- Journal Title
- Korean Journal of Internal Medicine
- ISSN
- 1226-3303
- Citation
- Korean Journal of Internal Medicine vol. 38, no. 5, pp. 683 - 691
- Keywords
- Drug-eluting stents; Percutaneous coronary intervention; Prospective studies; Registries
- Publisher
- Korean Association of Internal Medicine
- Indexed
- SCIE; SCOPUS; KCI
- Document Type
- Article
- Abstract
- Background/Aims: The Genoss DES™ is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt-chromium stent platform and thin strut. Although the safety and effectiveness of this stent have been previously investigated, real-world clinical outcomes data are lacking. Therefore, the aim of this prospective, multicenter trial was to evaluate the clinical safety and effectiveness of the Genoss DES™ in all-comer patients undergoing percutaneous coronary intervention. Methods: The Genoss DES registry is a prospective, single-arm, observational trial for evaluation of clinical outcomes after Genoss DES™ implantation in all-comer patients undergoing percutaneous coronary intervention from 17 sites in South Korea. The primary endpoint was a device-oriented composite outcome of cardiac death, target vessel-related myocardial infarction (MI), and clinically driven target lesion revascularization (TLR) at 12 months. Results: A total of 1,999 patients (66.4 ± 11.1 years of age; 72.8% male) were analyzed. At baseline, 62.8% and 36.7% of patients had hypertension and diabetes, respectively. The implanted stent number, diameter, and length per patient were 1.5 ± 0.8, 3.1 ± 0.5 mm, and 37.0 ± 25.0 mm, respectively. The primary endpoint occurred in 1.8% patients, with a cardiac death rate of 1.1%, target vessel-related MI rate of 0.2%, and clinically driven TLR rate of 0.8%. Conclusions: In this real-world registry, the Genoss DES™ demonstrated excellent safety and effectiveness at 12 months among all-comer patients undergoing percutaneous coronary intervention. These findings suggest that the Genoss DES™ may be a viable treatment option for patients with coronary artery disease. © 2023 The Korean Association of Internal Medicine.
- DOI
- 10.3904/kjim.2023.129
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML